Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs

Go back to Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 127.54 -0.08 (0.06%)
Previous Close $127.62    52 Week High $118.49 
Open $127.85    52 Week Low $55.00 
Day High $128.72    P/E N/A 
Day Low $126.88    EPS $-0.56 
Volume 605,058